Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer

Kaburagi,Takayuki; Satoh,Hiroaki; Hayashihara,Kenji; Endo,Takeshi; Hizawa,Nobuyuki; Kurishima,Koichi; Nishimura,Yoshihiro; Hashimoto,Toshio; Nakamura,Hiroyuki; Kishi,Koji; Inagaki,Masaharu; Nawa,Takeshi; Ichimura,Hideo; Ishikawa,Hiroichi; Kagohashi,Katsunori; Fukuoka,Toshihiko; Shinohara,Yoko; Kamiyama,Koichi; Sato,Yukio; Sakai,Mitsuaki; Matsumura,Takeshi; Uchiumi,Keiko; Furukawa,Kinya

doi:10.3892/ol.2012.1048

February 2013 Volume 5 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February 2013 Volume 5 Issue 2

Full Size Image

Article

Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer

Authors:
- Takayuki Kaburagi
- Hiroaki Satoh
- Kenji Hayashihara
- Takeshi Endo
- Nobuyuki Hizawa
- Koichi Kurishima
- Yoshihiro Nishimura
- Toshio Hashimoto
- Hiroyuki Nakamura
- Koji Kishi
- Masaharu Inagaki
- Takeshi Nawa
- Hideo Ichimura
- Hiroichi Ishikawa
- Katsunori Kagohashi
- Toshihiko Fukuoka
- Yoko Shinohara
- Koichi Kamiyama
- Yukio Sato
- Mitsuaki Sakai
- Takeshi Matsumura
- Keiko Uchiumi
- Kinya Furukawa
View Affiliations / Copyright

Affiliations: Division of Respiratory Medicine, Ibaraki Prefectural Central Hospital and Regional Cancer Center, Kasama 309-1793, Japan, Mito Medical Center, University of Tsukuba, Mito 310-0015, Japan, Ibaraki Higashi Hospital, Tokai 319-1113, Japan, Mito Medical Center Hospital, Ibaraki 311‑3193, Japan, University of Tsukuba Hospital, Tsukuba 305-8575, Japan, Mito Chuo Hospital, Mito 311-1135, Japan, Mito Saiseikai Hospital, Mito 311-4198, Japan, Tokyo Medical University Kasumigaura Hospital, Ami 300-0395, Japan, Tsuchiura Kyodo General Hospital and Regional Cancer Center, Tsuchiura 300-0053, Japan, Hitachi General Hospital, Hitachi 317-0077, Japan, Tsukuba Medical Center Hospital and Regional Cancer Center, Tsukuba 305-0005, Japan, JA Toride Medical Center, Toride 302‑0022, Japan, Tsukuba Kinen Hospital, Tsukuba 300‑2622, Japan, Ibaraki Seinan General Hospital, Sakai 306-0433, Japan
Pages: 435-439
|
Published online on: November 27, 2012

https://doi.org/10.3892/ol.2012.1048
Expand metrics +

Abstract

To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based observational study. The study involved 307 patients treated with erlotinib at 14 sites (17 departments) in Ibaraki (Japan) between December 2007 and December 2010. The tumor response and disease control rates were 11.1 and 46.3% in all patients, respectively. The median time to treatment failure and survival time were 1.6 months (95% confidence interval, 41‑57 days) and 5.3 months (134‑181 days) in all patients, respectively. Survival was significantly prolonged in EGFR mutation-positive patients compared with negative patients. EGFR mutation-negative patients who presented with a skin rash had significantly prolonged survival compared with those without a skin rash. The most common adverse event was skin disorder, followed by diarrhea. Although 45.6% of the patients in this study received erlotinib as a fourth-line or subsequent treatment, the results from this study were similar to those of clinical studies. We deduce that erlotinib is effective against NSCLC and is tolerated in clinical practice.

View Figures

View References

1.	Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo controlled, multicentre study (Iressa Survival Evaluating in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar
2.	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Inoue A, Kobayashi K, Usui K, et al: First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 27:1394–1400. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Kobayashi K, Inoue A, Maemondo M, et al: First line gefitinib versus first line chemotherapy by CBDCA plus paclitaxel in NSCLC patients with EGFR mutations: a Phase III study (002) by North East Japan (NEJ) Gefitinib study group. J Clin Oncol. 27(Suppl): 15s2009.(abstr 8016).
5.	Mok T, Wu YL, Thongprasert S, et al: Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Ann Oncol. 19(Suppl 8): abst LBA4. 2008.
6.	Bezjak A, Tu D, Seymour L, et al National Cancer Institute of Canada Clinical Trials Group Study BR.21: Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 24:3831–3837. 2006. View Article : Google Scholar
7.	Kubota K, Nishiwaki Y, Tamura T, et al: Efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non-small-cell lung cancer: a phase II study. J Thoracic Oncol. 3:1439–1445. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Pirker R, Su W, Rooneem R, et al: Clinical outcome with erlotinib in relation to biomarker status: analysis from the open-label TRUST study in advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 19(Suppl 8): 265P2008.
9.	Massuti B, Moran T, Porta R, et al: Multicenter prospective trial of customized erlotinib for advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial. J Clin Oncol. 27(Suppl): 15s2009.(abstr 8023).
10.	Cappuzzo F, Ciuleanu T, Stelmakh L, et al: SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol. 27(Suppl): 15s2009.(abstr 8001).
11.	Hayashibara K, Satoh H, Shinohara Y, et al: A population study of gefitinib in patients with non-small-cell lung cancer. Med Oncol. 26:222–227. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Ciuleanu T, Stelmakh L, Cicenas S, et al: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 13:300–308. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles